Page last updated: 2024-10-23

aspirin and Cognitive Dysfunction

aspirin has been researched along with Cognitive Dysfunction in 23 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.

Research Excerpts

ExcerptRelevanceReference
"Aspirin does not have a large proportional effect on the risk of dementia."9.51Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022)
"To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals."9.34Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. ( Chong, TTJ; Ernst, ME; Kirpach, B; Lockery, JE; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Reid, CM; Ryan, J; Shah, RC; Storey, E; Trevaks, R; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2020)
" In the overall trial rivaroxaban plus aspirin reduced ischemic stroke by 49% (0."7.96Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. ( A A Fox, K; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Casanova, A; Connolly, SJ; Dagenais, GR; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Hart, RG; Keltai, K; Keltai, M; Kim, JH; Liang, Y; Liu, L; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; O'Donnell, M; Piegas, LS; Pogosova, N; Probstfield, JL; Reeh, KW; Ryden, L; Sharma, M; Smith, EE; Störk, S; Tonkin, AM; Varigos, JD; Vinereanu, D; Yusuf, S; Zhu, J, 2020)
"Aspirin does not have a large proportional effect on the risk of dementia."5.51Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022)
"Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively."5.34Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020)
"To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals."5.34Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. ( Chong, TTJ; Ernst, ME; Kirpach, B; Lockery, JE; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Reid, CM; Ryan, J; Shah, RC; Storey, E; Trevaks, R; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2020)
" In the overall trial rivaroxaban plus aspirin reduced ischemic stroke by 49% (0."3.96Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. ( A A Fox, K; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Casanova, A; Connolly, SJ; Dagenais, GR; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Hart, RG; Keltai, K; Keltai, M; Kim, JH; Liang, Y; Liu, L; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; O'Donnell, M; Piegas, LS; Pogosova, N; Probstfield, JL; Reeh, KW; Ryden, L; Sharma, M; Smith, EE; Störk, S; Tonkin, AM; Varigos, JD; Vinereanu, D; Yusuf, S; Zhu, J, 2020)
"The effects of B vitamins on mild cognitive impairment (MCI) patients' cognition have been mixed, suggesting the existence of moderating factors."3.11B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy. ( Gong, X; Kwok, T; Luo, Y; Shi, L; Wu, Y, 2022)
"Cerebral small vessel disease is a progressive disease of the brain's deep perforating blood vessels."2.82Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. ( Chiang, LLW; Hafdi, M; Kwan, J; Myint, PK; Quinn, TJ; Wong, LS, 2022)
"Aspirin co-treatment rescued DNMTs activation and BDNF IV hypermethylation, and mitigated the recession in BDNF mRNA and protein induced by B[a]P treatment."1.72Aspirin ameliorates the cognition impairment in mice following benzo[a]pyrene treatment via down-regulating BDNF IV methylation. ( Bai, J; Cao, J; Hao, Z; Li, H; Li, X; Li, Y; Liu, A; Wang, Z; Xia, N; Zhang, H; Zhang, Z, 2022)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (26.09)24.3611
2020's17 (73.91)2.80

Authors

AuthorsStudies
Lin, X1
Banaszak-Holl, J1
Xie, J1
Ward, SA2
Brodaty, H1
Storey, E3
Shah, RC4
Murray, A2
Ryan, J5
Orchard, SG5
Fitzgerald, SM1
McNeil, JJ4
Mone, P1
Trimarco, B1
Santulli, G1
Wu, Y2
Smith, AD1
Refsum, H1
Kwok, T2
Broder, JC2
Lockery, JE2
Gilmartin-Thomas, JF1
Fravel, MA1
Owen, AJ1
Woods, RL4
Wolfe, R3
Murray, AM3
Ernst, ME4
Li, Y1
Cao, J1
Hao, Z1
Liu, A1
Li, X1
Li, H1
Xia, N1
Wang, Z1
Zhang, Z1
Bai, J1
Zhang, H1
Parish, S1
Mafham, M1
Offer, A1
Barton, J1
Wallendszus, K1
Stevens, W1
Buck, G1
Haynes, R1
Collins, R1
Bowman, L1
Armitage, J1
Kwan, J1
Hafdi, M1
Chiang, LLW1
Myint, PK1
Wong, LS1
Quinn, TJ1
Gong, X1
Shi, L1
Luo, Y1
Mehta, RS1
Kochar, B1
Zhou, Z2
Chung, P1
Yang, K1
Lockery, J1
Fravel, M1
Mahady, S1
Chan, AT1
Tonkin, AM2
Zoungas, S2
Lacaze, P2
Yu, C1
Watts, GF1
Hussain, SM1
Beilin, LJ1
Stocks, N1
Zhu, C1
Reid, CM2
Chong, TT1
Sood, A1
Sheets, KM1
Nelson, MR2
Kwon, HS1
Lee, D1
Lee, MH1
Yu, S1
Lim, JS1
Yu, KH1
Oh, MS1
Lee, JS1
Hong, KS1
Lee, EJ1
Kang, DW1
Kwon, SU1
Lee, TC1
Qian, M1
Liu, Y1
Graham, S1
Mann, DL1
Nakanishi, K1
Teerlink, JR1
Lip, GYH1
Freudenberger, RS1
Sacco, RL1
Mohr, JP1
Labovitz, AJ1
Ponikowski, P1
Lok, DJ1
Matsumoto, K1
Estol, C1
Anker, SD1
Pullicino, PM1
Buchsbaum, R1
Levin, B1
Thompson, JLP1
Homma, S1
Di Tullio, MR1
Knopman, DS1
Petersen, RC1
Chong, TTJ1
Williamson, JD1
Trevaks, R1
Kirpach, B1
Newman, AB1
Amidzic, A1
Tiro, N1
Sharma, M1
Hart, RG1
Smith, EE1
Bosch, J1
Eikelboom, JW1
Connolly, SJ1
Dyal, L1
Reeh, KW1
Casanova, A1
Diaz, R1
Lopez-Jaramillo, P1
Ertl, G1
Störk, S1
Dagenais, GR1
Lonn, EM1
Ryden, L1
Varigos, JD1
Bhatt, DL1
Branch, KRH1
Probstfield, JL1
Kim, JH1
O'Donnell, M1
Vinereanu, D1
A A Fox, K1
Liang, Y1
Liu, L1
Zhu, J1
Pogosova, N1
Maggioni, AP1
Avezum, A1
Piegas, LS1
Keltai, K1
Keltai, M1
Berkowitz, SD1
Yusuf, S1
Patel, S1
Sanborn, D1
Issa, M1
Weng, J1
Zhao, G1
Weng, L1
Guan, J1
Woods, R1
McNeil, J1
Ferrari, C1
Lombardi, G1
Polito, C1
Lucidi, G1
Bagnoli, S1
Piaceri, I1
Nacmias, B1
Berti, V1
Rizzuto, D1
Fratiglioni, L1
Sorbi, S1
Fink, HA1
Jutkowitz, E1
McCarten, JR1
Hemmy, LS1
Butler, M1
Davila, H1
Ratner, E1
Calvert, C1
Barclay, TR1
Brasure, M1
Nelson, VA1
Kane, RL1
Walker, AK1
Chang, A1
Ziegler, AI1
Dhillon, HM1
Vardy, JL1
Sloan, EK1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes[NCT00135226]Phase 415,480 participants (Actual)Interventional2005-03-31Active, not recruiting
LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.[NCT03451591]Phase 2/Phase 3363 participants (Actual)Interventional2018-01-08Completed
A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203]Phase 4255 participants (Actual)Interventional2013-07-17Active, not recruiting
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White[NCT00847860]Phase 4200 participants (Actual)Interventional2008-03-31Completed
Stroke and Coated-Platelets - A Translational Research Initiative[NCT04698031]Phase 4152 participants (Anticipated)Interventional2022-03-30Recruiting
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)[NCT03061006]Phase 4101 participants (Actual)Interventional2017-04-03Completed
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[NCT00041938]Phase 32,305 participants (Actual)Interventional2002-10-31Completed
Aspirin in Reducing Events in the Elderly[NCT01038583]19,114 participants (Actual)Observational2010-01-31Active, not recruiting
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]Phase 327,395 participants (Actual)Interventional2013-02-28Completed
A Multidomain Intervention Program for Older People With Dementia: A Pilot Study[NCT04948450]60 participants (Anticipated)Interventional2022-11-24Active, not recruiting
Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.[NCT05262257]Early Phase 1120 participants (Anticipated)Interventional2022-04-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)

"Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin157
Placebo Aspirin158

Number of Participants With Combined End-point of Serious Vascular Events (SVEs) or Revascularizations

"Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of SVE or revascularization (including coronary and non-coronary revascularizations)." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin833
Placebo Aspirin936
Omega-3882
Placebo Omega-3887

Number of Participants With Event: Any Cancer

"Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.~A single participant may have had multiple cancers." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin897
Placebo Aspirin887
Omega-3894
Placebo Omega-3890

Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)

Includes fatal and non-fatal events. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Omega-3166
Placebo Omega-3135

Number of Participants With Event: Breast Cancer

Includes fatal and non-fatal cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin97
Placebo Aspirin96
Omega-3103
Placebo Omega-390

Number of Participants With Event: Genitourinary Cancer

Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin332
Placebo Aspirin294
Omega-3323
Placebo Omega-3303

Number of Participants With Event: Hematological Cancer

Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin88
Placebo Aspirin86
Omega-394
Placebo Omega-380

Number of Participants With Event: Melanoma

Includes fatal and non-fatal melanomas. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin50
Placebo Aspirin59
Omega-355
Placebo Omega-354

Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only)

Includes fatal and non-fatal events, excludes atrial fibrillation. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Omega-383
Placebo Omega-399

Number of Participants With Event: Other Cancer

Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin25
Placebo Aspirin30
Omega-323
Placebo Omega-332

Number of Participants With Event: Other Gastrointestinal Cancer (Aspirin Comparison Only)

Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin87
Placebo Aspirin82

Number of Participants With Event: Respiratory Cancer

Includes fatal and non-fatal cancers. Includes lung and larynx cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin101
Placebo Aspirin103
Omega-3104
Placebo Omega-3100

Number of Participants With Event: Unspecified Cancer

Includes fatal and non-fatal cancers of unknown type. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin26
Placebo Aspirin31
Omega-325
Placebo Omega-332

Number of Participants With Fatal Event: All Stroke

Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin38
Placebo Aspirin34
Omega-335
Placebo Omega-337

Number of Participants With Fatal Event: All-cause Mortality

'All-cause mortality' includes all recorded deaths. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin748
Placebo Aspirin792
Omega-3752
Placebo Omega-3788

Number of Participants With Fatal Event: Cancer

Fatal 'Cancer' events include any death attributed to cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin309
Placebo Aspirin315
Omega-3305
Placebo Omega-3319

Number of Participants With Fatal Event: Coronary

Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin105
Placebo Aspirin122
Omega-3100
Placebo Omega-3127

Number of Participants With Fatal Event: External Cause

Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin18
Placebo Aspirin21
Omega-317
Placebo Omega-322

Number of Participants With Fatal Event: Other Medical

Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin126
Placebo Aspirin157
Omega-3158
Placebo Omega-3125

Number of Participants With Fatal Event: Other Vascular

Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin67
Placebo Aspirin70
Omega-361
Placebo Omega-376

Number of Participants With Fatal Event: Respiratory

Fatal 'Respiratory' events include any death attributed to respiratory causes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin82
Placebo Aspirin69
Omega-373
Placebo Omega-378

Number of Participants With Fatal Event: Unknown Cause

Any death for which the cause is not known. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin3
Placebo Aspirin4
Omega-33
Placebo Omega-34

Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)

"The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of any major bleed, defined as:~any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or~sight-threatening eye bleeding; or~any other serious bleeding episode." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin314
Placebo Aspirin245

Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)

"The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any Serious Vascular Event (SVE), defined as:~non-fatal myocardial infarction; or~non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or~vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62])." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin658
Placebo Aspirin743
Omega-3689
Placebo Omega-3712

Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death

The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years

Interventionevents per 100 patient-years (Number)
Aspirin7.93
Warfarin7.47

Event Rate Per 100 Patient Years of Death Component of Secondary Composite Outcome

Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin4.41
Warfarin4.43

Event Rate Per 100 Patient Years of Heart Failure Hospitalization Component of Secondary Composite Outcome.

Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin5.67
Warfarin6.79

Event Rate Per 100 Patient Years of Intracerebral Hemorrhage Component of Secondary Composite Outcome

Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin0.06
Warfarin0.11

Event Rate Per 100 Patient Years of Ischemic Stroke Component of Secondary Composite Outcome

Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin1.14
Warfarin0.57

Event Rate Per 100 Patient Years of Myocardial Infarction Component of Secondary Composite Outcome

Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin0.87
Warfarin0.80

Event Rate Per 100 Patient-years for Composite Endpoint of Hospitalization for Heart Failure, Myocardial Infarction, Ischemic Stroke, Intracerebral Hemorrhage, or Death.

"The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.~Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25." (NCT00041938)
Timeframe: From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.

Interventionevents per 100 patient-years (Number)
Aspirin12.15
Warfarin12.70

Event Rate Per 100 Patient-years for Death

Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of primary composite outcome, up to 6 years

Interventionevents per 100 patient-years (Number)
Aspirin6.52
Warfarin6.63

Event Rate Per 100 Patient-years for Intracerebral Hemorrhage

Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years

Interventionrate per 100 patient years (Number)
Aspirin0.05
Warfarin0.12

Event Rate Per 100 Patient-years for Ischemic Stroke

Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years

Interventionrate per 100 patient years (Number)
Aspirin1.36
Warfarin0.72

Rate Per 100 Patient Years of Major Hemorrhage

Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until end of scheduled follow-up, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin0.87
Warfarin1.78

Rate Per 100 Patient-years of Minor Hemorrhage.

Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the end of scheduled follow-up, up to 6 years

Interventionevents per 100 patient-years (Number)
Aspirin7.34
Warfarin11.6

All-cause Mortality

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg313
Rivaroxaban 5mg + Aspirin Placebo366
Rivaroxaban Placebo + Aspirin 100mg378

All-cause Mortality in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg282

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg389
Rivaroxaban 5mg + Aspirin Placebo453
Rivaroxaban Placebo + Aspirin 100mg516

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg329
Rivaroxaban 5mg + Aspirin Placebo397
Rivaroxaban Placebo + Aspirin 100mg450

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg379
Rivaroxaban 5mg + Aspirin Placebo448
Rivaroxaban Placebo + Aspirin 100mg496

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg353

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg288
Rivaroxaban 5mg + Aspirin Placebo255
Rivaroxaban Placebo + Aspirin 100mg170

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg138

Reviews

2 reviews available for aspirin and Cognitive Dysfunction

ArticleYear
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
    The Cochrane database of systematic reviews, 2022, 07-14, Volume: 7

    Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat

2022
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
    Annals of internal medicine, 2018, 01-02, Volume: 168, Issue:1

    Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin

2018
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
    Annals of internal medicine, 2018, 01-02, Volume: 168, Issue:1

    Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin

2018
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
    Annals of internal medicine, 2018, 01-02, Volume: 168, Issue:1

    Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin

2018
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
    Annals of internal medicine, 2018, 01-02, Volume: 168, Issue:1

    Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin

2018

Trials

7 trials available for aspirin and Cognitive Dysfunction

ArticleYear
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
    European heart journal, 2022, 06-01, Volume: 43, Issue:21

    Topics: Aspirin; Cognition; Cognitive Dysfunction; Dementia; Diabetes Mellitus; Humans

2022
B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy.
    Journal of Alzheimer's disease : JAD, 2022, Volume: 89, Issue:4

    Topics: Aspirin; Atrophy; Cognition; Cognitive Dysfunction; Dietary Supplements; Folic Acid; Frontal Lobe; H

2022
Association of Proton Pump Inhibitor Use With Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study.
    Gastroenterology, 2023, Volume: 165, Issue:3

    Topics: Aged; Aspirin; Cognition; Cognitive Dysfunction; Humans; Prospective Studies; Proton Pump Inhibitors

2023
Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.
    Neurology, 2023, Nov-27, Volume: 101, Issue:22

    Topics: Aged; Alzheimer Disease; Apolipoproteins E; Aspirin; Cognition; Cognitive Dysfunction; Female; Human

2023
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
    Journal of neurology, 2020, Volume: 267, Issue:3

    Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle

2020
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
    Neurology, 2020, 07-21, Volume: 95, Issue:3

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cognitive Dysfunction; De

2020
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.
    Contemporary clinical trials, 2013, Volume: 36, Issue:2

    Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Cardi

2013

Other Studies

14 other studies available for aspirin and Cognitive Dysfunction

ArticleYear
Similar mortality risk in incident cognitive impairment and dementia: Evidence from the ASPirin in Reducing Events in the Elderly (ASPREE) trial.
    Journal of the American Geriatrics Society, 2021, Volume: 69, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Cognitive Dysfunction; Dementi

2021
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021.
    European heart journal. Cardiovascular pharmacotherapy, 2022, 05-05, Volume: 8, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cognitive Dysfunction; Dementia; Humans; Warfar

2022
Effectiveness of B Vitamins and Their Interactions with Aspirin in Improving Cognitive Functioning in Older People with Mild Cognitive Impairment: Pooled Post-Hoc Analyses of Two Randomized Trials.
    The journal of nutrition, health & aging, 2021, Volume: 25, Issue:10

    Topics: Aged; Aspirin; Cognition; Cognitive Dysfunction; Humans; Randomized Controlled Trials as Topic; Vita

2021
Anticholinergic medication burden and cognitive function in participants of the ASPREE study.
    Pharmacotherapy, 2022, Volume: 42, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Cholinergic Antagonists; Cognition; Cognitive Dysfunction; Disable

2022
Aspirin ameliorates the cognition impairment in mice following benzo[a]pyrene treatment via down-regulating BDNF IV methylation.
    Neurotoxicology, 2022, Volume: 89

    Topics: Animals; Aspirin; Benzo(a)pyrene; Brain-Derived Neurotrophic Factor; Cognition; Cognitive Dysfunctio

2022
Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF.
    JACC. Heart failure, 2019, Volume: 7, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Cognitive Dysfunction; Female; Fibrinolytic Agents; Heart Failure, Sy

2019
The quest for dementia prevention does not include an aspirin a day.
    Neurology, 2020, 07-21, Volume: 95, Issue:3

    Topics: Aspirin; Cognitive Dysfunction; Dementia, Vascular; Humans

2020
Kinking of Bilateral Internal Carotid Arteries as Cause of Cognitive Dysfunction.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2020, Volume: 74, Issue:1

    Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Bosnia and Herzegovina; Bromazepam; Carotid Artery,

2020
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
    Stroke, 2020, Volume: 51, Issue:10

    Topics: Aged; Aspirin; Brain; Brain Infarction; Cognitive Dysfunction; Drug Therapy, Combination; Factor Xa

2020
57-Year-Old Woman With Weakness and Word-Finding Difficulties.
    Mayo Clinic proceedings, 2021, Volume: 96, Issue:2

    Topics: Adenocarcinoma, Clear Cell; Antibodies, Antiphospholipid; Aspirin; Biomarkers, Tumor; Cerebral Infar

2021
Aspirin using was associated with slower cognitive decline in patients with Alzheimer's disease.
    PloS one, 2021, Volume: 16, Issue:6

    Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cog

2021
The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies.
    Internal medicine journal, 2017, Volume: 47, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Biological Specimen Banks; Cardio

2017
Alzheimer's Disease Progression: Factors Influencing Cognitive Decline.
    Journal of Alzheimer's disease : JAD, 2018, Volume: 61, Issue:2

    Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Aspirin; Cognitive Dysfuncti

2018
Low dose aspirin blocks breast cancer-induced cognitive impairment in mice.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Behavior, Animal; Cognitive Dysfunction;

2018